Cárdenas‐Jaén K, Archibugi L, Poropat G, et al. - Given that post‐endoscopic retrograde cholangiopancreatography (ERCP) acute pancreatitis (PEP) is a frequent complication of this endoscopic procedure, researchers conducted this international, multicenter, prospective cohort study to ascertain if statins and chronic acetylsalicylic acid (ASA) intake are correlated with a lower risk of PEP. Consecutive patients undergoing ERCP in seven European centers were involved. In total, 1,150 patients were involved, 70 (6.1%) of whom developed PEP. According to results, 8.1% of statins users developed PEP vs. 5.4% of non‐users. No link between statin use and PEP incidence was seen in multivariate analysis. As PEP was considered mild in 92.0% of statin users and in 82.2% of non‐statin users, statin use seemed to have no effect on PEP severity. Chronic ASA use was not associated with PEP either. Protective factors against PEP were alcohol abuse and prior endoscopic biliary sphincterotomy, while risk factors were > 1 pancreatic guidewire passage, normal bilirubin values, and duration of the procedure > 20 minutes. The lower risk or a milder course of PEP is not associated with the use of statins or ASA.